Paul Chung

Assistant Professor

Thomas Jefferson University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Paul Chung is an Assistant Professor at Thomas Jefferson University in the United States. His research encompasses various aspects of urology, particularly focusing on conditions related to penile and urethral dysfunction. Recent articles authored by Professor Chung explore the implications of Marfan's syndrome on Peyronie's disease, treatment trends for priapism, and the management of inflatable penile prostheses. He is actively engaged in evaluating treatment methodologies through extensive data analysis using the TriNetX research network.

Articles (16)

Year:

2026

Year:

2025

Hydrophilic penile prosthesis (PP) surfaces removed during revision surgery may potentially rebind antiseptics and maintain antimicrobial efficacy ex vivo. Coloplast Titan reservoirs and cylinders were retrieved during revision surgery for mechanical failure. Congo Red staining and contact angle measurements were performed to evaluate the integrity of the hydrophilic surface. Fluorescent antibiotic binding was performed by submerging discs for 3 min in either fluorescein-isothiocyanate (FITC) labeled or unlabeled vancomycin at 2 mg/mL. Fluorescence was quantified via ImageJ. 8 mm discs were submerged for 3 min in normal saline (NS), 0.05% chlorhexidine gluconate, or a 2 mg/mL vancomycin and 160 μg/mL gentamicin (VG) antibiotic, then incubated with 10 5 colony-forming units per milliliter of methicillin-sensitive Staphylococcus aureus ATCC25923 for 48 h then counted. Mann-Whitney U and one-way ANOVA tests were performed to compare outcomes, p < 0.05 considered significant. All PP tested for binding with FITC-vancomycin showed significant increases in fluorescence relative to unlabeled vancomycin controls (p < 0.0001). All explanted and control PP exhibited significant decreases in bacterial counts on VG-treated surfaces relative to NS controls (p < 0.01). The hydrophilic surface of the reservoir and cylinders maintain their integrity based on Congo Red staining and rebind VG antibiotics effectively based on microbiology and fluorescent binding studies.

Year:

2025

We describe the management trends of patients suffering from any priapism and evaluate the risks of developing priapism after intracavernosal injections (ICI) performed in office. We queried TriNetX for two separate male adult cohorts - those presenting with any priapism based on International Classification of Disease code, N48.3 (priapism) and those who underwent ICI in office based on Current Procedural Terminology code, 54235 (injection of corpora cavernosa with pharmacologic agent[s]). We evaluated treatment options for these patients after any priapism and described demographic risks for developing priapism after ICI performed in office. There were 17,545 priapism encounters and 26,104 usages of ICI in the office. Most common treatment for any priapism was corporal irrigation/injection of medications (11.3%). Patients presenting with priapism after ICI were younger (age > 65 years, OR 0.44 [95% CI 0.38–0.51], p < 0.01) and had a higher prevalence of mood disorders (20% vs 14%), behavioral disorders (7% vs 2%) and sickle cell disease (6% vs <1%). They were less likely to have diabetes (14% vs 22%), hypertension (33% vs 40%), prostate cancer (13% vs 25%) or have taken sildenafil or tadalafil (29–30% vs 35–38%). For patients administering ICI, proper screening and counseling of priapism is important to reduce complications.

Year:

2025

Year:

2025

Prostate cancer treatment-related erectile dysfunction and stress urinary incontinence are commonly treated with inflatable penile prosthesis (IPP) or artificial urinary sphincter (AUS). Given the association with androgens and penile/urethral health, we aim to evaluate whether patients on androgen deprivation therapy (ADT) undergoing IPP or AUS surgery are at increased risk for reintervention, complication, or infection. We queried the TriNetX database for adult males receiving IPP or AUS. The ADT cohort included those on ADT 3 months before or any time after surgery. We performed sub-analysis for leuprolide and bicalutamide. Cohorts and outcomes were defined by Current Procedural Terminology and International Classification of Diseases codes. Propensity score matching was performed using age, prostate cancer, history of prostatectomy, and history of radiation. Outcomes were reintervention (revision, removal, or replacement), infection, and complication. Analytics were performed in March 2024. 13,432 patients received an IPP and 5676 received an AUS, 465 and 745 of whom were on ADT, respectively. The only significant AUS analysis was for patients on abiraterone having fewer reinterventions (10.5% vs 20.8%, RR = 0.50 [0.29, 0.88]). Patients receiving an IPP with ADT had fewer reinterventions (7.2% vs 12%, RR = 0.60 [0.39, 0.92]) and complications (12.7% vs 18.5%, RR = 0.68 [0.49, 0.95]). Those on a GnRH agonist had fewer reinterventions (7.4% vs 11.7%, RR = 0.63 [0.41, 0.98]) for IPP. Patients receiving an IPP on bicalutamide had fewer reinterventions ( <5.2%* vs 10.8%, RR = 0.48 [0.23, 0.99]) and on leuprolide had fewer complications (12.2% vs 19.3%, RR = 0.63 [0.43, 0.91]). The remainder of analyses showed no significant differences. Patients with IPP or AUS do not fare worse on ADT. Further evaluation into the duration of ADT may provide clinical context, but based on these results, ADT should not limit implant surgery.

Year:

2025

Background: Urethral strictures and bladder neck contractures (BNCs) can be significantly morbid for patients and may require intervention for effective urinary drainage. We hypothesized patients with abnormal scarring disorders, such as keloids or hypertrophic scars, are at elevated risks of urethroplasty failure as well as postprocedural urethral strictures and BNCs. Methods: We queried the TriNetX database to determine the risk of urethroplasty failure for patients with abnormal scarring disorders compared to controls. We also investigated the risk of developing urethral strictures and BNCs for patients undergoing various endourology procedures. Results are reported in terms of risk ratio (RR) with 95% confidence interval (CI). Statistical significance was considered when the CI did not include 1.0. Propensity score matching was performed to limit confounding. Notably, TriNetX rounds values < 10 to 10 for patient anonymity (denoted by *). Results: Urethroplasty patients with scarring pathology needed a second procedure more than twice as often (36.2% vs. <17.2%*, RR = 2.1, 95%CI 1.1–4.1). Following cystoscopy, there was no difference in urethral stricture rates for patients with scarring disorders (2.7% vs. 2.6%, RR = 1.1, 95%CI 0.85–1.3). These patients also showed similar rates of BNCs (7.5% vs. 5.3%, RR = 1.4, 95%CI 0.84–2.3) and urethral strictures (5.9% vs. 5.3%, RR = 1.1, 95%CI 0.68–1.8) after transurethral bladder outlet procedures. Conclusions: Patients with scarring disorders showed much higher urethroplasty failure rates. They experienced similar rates of urethral strictures and BNC formation after endoscopic procedures. These novel findings underscore the importance of recognizing abnormal scarring conditions during preoperative assessments, guiding clinicians in counseling patients and tailoring operative interventions.

Year:

2025

Year:

2024

Year:

2024

Prostate cancer treatment-related erectile dysfunction and stress urinary incontinence are commonly treated with inflatable penile prosthesis (IPP) or artificial urinary sphincter (AUS). Given the association with androgens and penile/urethral health, we aim to evaluate whether patients on Androgen Deprivation Therapy (ADT) undergoing IPP or AUS are at increased risk for reintervention, complication, or infection. We queried the TriNetX database for adult males receiving IPP or AUS. The ADT cohort included those on ADT 3 months before or any time after surgery. We performed sub-analysis for leuprolide and bicalutamide. Cohorts and outcomes were defined by Current Procedural Terminology and International Classification of Diseases codes. Propensity score matching was performed using age, prostate cancer, history of prostatectomy, and history of radiation. Outcomes were reintervention (revision, removal, or replacement), infection, and complication. Analytics were performed in March 2024. 13,432 patients received an IPP and 5676 received an AUS, 465 and 745 of whom were on ADT, respectively. Patients receiving an IPP with ADT had fewer reinterventions (7.2% vs 12%, RR = 0.60 [0.39, 0.92]) and complications (12.7% vs 18.5%, RR = 0.68 [0.49, 0.95]). Patients receiving an IPP on Bicalutamide or Leuprolide had fewer reinterventions (< 5.2%* vs 10.8%, RR = 0.48 [0.23, 0.99]) and complications (12.2% vs 19.3%, RR = 0.63 [0.43, 0.91]). The remainder of analyses, including comparisons of patients on antiandrogens against those not on ADT, GnRH antagonists against those not on ADT, and abiraterone against those not on ADT, showed no significant differences. There were ≤10 instances of reintervention for IPP patients on bicalutamide, thus TriNetX rounded up to 10 (denoted by *) to protect patient identity. Patients with IPP or AUS do not fare worse on ADT. Further evaluation into the duration of ADT may provide clinical context, but based on these results, ADT should not limit implant surgery.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2020

Year:

2020

Collaborators (1)

Jeffrey Robinson

Associate Professor

University of Washington

UNITED STATES
View details